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Mycobacterium tuberculosis-induced cellular aggregation is essential for granuloma formation and may
assist establishment and early spread ofM. tuberculosis infection. TheM. tuberculosis ESX1 mutant, which
has a non-functional type VII secretion system, induced signiﬁcantly less production of the host
macrophage-derived chemokine fractalkine (CX3CL1). Upon infection of human macrophages ESX1-
dependent fractalkine production mediated selective recruitment of CD11bþ monocytic cells and
increased infection of neighbouring cells consistent with early local spread of infection. Fractalkine levels
were raised in vivo at tuberculous disease sites in humans and were signiﬁcantly associated with
increased CD11bþ monocytic cellular recruitment and extent of granulomatous disease. These ﬁndings
suggest a novel fractalkine-dependent ESX1-mediated mechanism in early tuberculous disease patho-
genesis in humans. Modulation of M. tuberculosis-mediated fractalkine induction may represent a po-
tential treatment option in the future, perhaps allowing us to switch off a key mechanism required by the
pathogen to spread between cells.
 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY license.1. Introduction
Mycobacterium tuberculosis (Mtb) remains the leading cause of
bacterial mortality world-wide [1]. Little is known about the
earliest events in human tuberculous infection during which the
inhaled bacillus must spread from permissive cell to cell and
establish its infective niche. Rapid availability of niche host cells
early on (i.e. during the ﬁrst 24e48 h) is essential for early estab-
lishment of infection and subsequent bacillary dissemination. The
percentage of macrophages, representing the primary niche of the
tubercle bacillus, in the human lungs is relatively low (ranging froment of Microbial and Cellular
f Health and Medical Science,
. Hingley-Wilson).
r Ltd. Open access under CC BY license3 to 19%) with approximately 1 macrophage per 9 ml lung volume
[2]. As such, a chemotactic call from the infected “Trojan horse”
aggregating more of these naive cells could increase niche avail-
ability, cellular infection and bacterial dissemination.
It is increasingly recognised that chemotaxis-driven aggregation
of macrophages is essential for establishment of the infectious
niche and early bacillary spread in the Mycobacterium marinum-
infected zebraﬁsh [3]. This pioneering study reported how early
granuloma formation (“macrophage inﬁltration and aggregation”)
in the zebrafish resulted in increased bacterial growth and spread.
Intriguingly, M. marinum’s ability to establish infection and
dissemination through early cellular aggregationwas dependent on
region of difference 1 (RD1), themost strongly virulence-associated
genomic region of Mtb. Notably, the reduced cellular inﬁltration
observed in transparent zebraﬁsh embryos infected with the
M. marinum RD1 mutant was due to reduced ESAT-6-mediated
production of matrix metalloproteinase 9 (MMP-9) by epithelial
cells which neighbour the infected macrophages [4]. The role of.
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of infection has not hitherto been tested in M. tuberculosis in
humans.
Similarly to mutants of M. marinum, Mtb mutants without RD1
are highly attenuated yet unlike the zebraﬁsh pathogen they have
no defect in growth [5,6] and thus represent a pure pathology-
deﬁcient phenotype or pat mutant [7]. Mtb region of difference 1
(RD1) represents the primary attenuating deletion of the vaccine
strain Bacillus Calmette Guerin (BCG) [8] and spans a 9 gene region
from Rv3871-Rv3879, central to which are the highly antigenic
molecules early secreted antigen target-6 (ESAT-6) and culture
ﬁltrate protein-10 (CFP-10). Recently, RD1 was determined to be
part of a novel type VII secretion system called ESX1 which is
critical for virulence andwas recently determined to be required for
the survival of tubercle bacilli in the primate lung [9]. A number of
virulence mechanisms have been attributed to ESX1 including
phagosomal maturation arrest [10], cytosolic bacterial trans-
location [11] and host cell necrosis in cells 72 h post-infection
[5,12,13], although it is unknown which of these is the most
important in human tuberculosis in vivo.
The early virulence mechanisms utilised by the tubercle bacillus
to obtain and set up its infective niche are likely pivotal in deter-
mining the outcome of M. tuberculosis exposure and infection and
therefore important to elucidate. We hypothesised that ESX1 may
play a similarly crucial role in early monocyte recruitment and
bacterial dissemination in humans to that observed in the zebra-
ﬁsh. Using an M. tuberculosis mutant and human cells we assessed
the role of ESX1 in M. tuberculosis-induced chemokine-mediated
cellular aggregation and bacillary dissemination.
2. Materials and methods
2.1. Ethics statement
All samples were taken with approval from St. Mary’s REC for 5
years (REC Number: 07/H0712/85) and with written informed
consent. All animal work was carried out in accordance with the UK
Animal (Scientiﬁc Procedures) Act 1986 and was approved by the
animal use ethical committee of Oxford University.
2.2. Mtb growth
Mtb H37Rv was grown in Category III conditions on Mid-
dlebrook 7H9 (Becton Dickinson) medium plus 10% Middlebrook
OADC (oleic acid, albumin, dextrose and catalase; Becton Dick-
inson) supplement, 0.5% glycerol (Sigma Aldrich) and 0.05% Tween
80 (Sigma Aldrich) at 37 C at 100 rpm until they reached mid log
phase when aliquots were frozen for use in 10% glycerol and plated
out for colony forming units (CFU) on Middlebrook 7H10 agar
plates plus 10% OADC and 0.5% glycerol at 37 C for 2e3 weeks.
2.3. Infection experiments
Human THP-1 cells (a monocyte-derived cell line; American
Type Culture Collection: ATCC), human A549 alveolar epithelial
cells, murine J774 macrophage cells (ATCC), primary human
alveolar epithelial cells (ATCC) or primary MDMs (isolated as in
[5]) were infected at a multiplicity of infection (M.O.I) of 10:1, as
described in detail in5. THP-1 cells were pre-treated with 20 ng/ml
phorbol 12-myristate 13-acetate (PMA, Sigma Aldrich) for 18 h to
stimulate adherence prior to infection or activation. In brief, cells
were seeded in 12-well plates, or chamber slides (VWR) to
determine successful intracellular infection, at 5  105 cells/ml,
and, after infection with bacilli for 2 h, any extracellular bacilli
were washed off with warm RPMI and the media replaced. Forsupernatant analysis, the supernatant was removed and ﬁltered
using an ultra-free centrifugal ﬁlter device 0.22u (2 ml; Millipore)
prior to removal from the CL3 suite. The cells were harvested for
counting or ﬂow cytometry by scraping. Trypan blue (Sigma) was
used to determine viability, except in the ﬂow cytometry where a
viability stain was used (see below). To plate for extracellular CFUs
a dilution series was prepared and plated out as above and for
intracellular bacilli 0.1% Triton X-100 was used to lyse the cells
prior to diluting and plating out. The anti-human CX3CL1/frac-
talkine antibody (R and D systems) was added at 1 mg/ml, the
recombinant full length human CX3CL1/fractalkine (R and D sys-
tems) at 100 ng/ml, lipopolysaccharide at 10 ng/ml and picea-
tannol at 50 mM (Sigma Aldrich) for the stated time. For direct
observation of the infected monolayers, coverslips were added to
the well prior to the MDMs and staining was carried out using the
TB cold stain kit (BDH).
2.4. Flow cytometry
Washed cells were stained with aqua LIVE⁄DEAD Fixable Dead
Cell Stain Kit, (Invitrogen), CD3-Pe-Cy7 (e-bioscience), CD11b-APC-
Cy7 (BD bioscience) and FITC anti-human CX3CR1 (Cambridge
Bioscience) at 1:100 dilutions for 30 min. Unstained controls were
used to set voltages, single-stained controls for compensation and
ﬂuorescence minus one (FMO) controls for gate setting during
analysis. The samples were run on a Becton Dickinson LSR Fortessa
and analysed using FlowJo 9.3 (TreeStar,Inc). Events were gated on
live singlets then analysed for cell surface marker expression. Cells
infected with Mtb H37Rv-FITC were stained with aqua LIVE⁄DEAD
Fixable Dead Cell Stain Kit (Invitrogen) and then acquired on Becton
Dickinson LSR Fortessa before analysis with FlowJo 9.3. The murine
lung ﬂow cytometry panel was composed of annexin-V/propidium
iodide (AbCam), CD11b-APC-Cy7.7 (Becton Dickinson) and CD3-
Pacblue (Cambridge Bioscience). For the single stained controls
anti-rat/hamster murine beads were used (Invitrogen) and an un-
stained and FMO controls were also carried out. The samples were
run on a Beckman Coulter CyAn ADP and live singlet cells were
gated and analysed using Flowjo 9.3.
2.5. Murine experiments
Balb/C mice were infected intra-nasally with 300 CFU Mtb
H37Rv or Mtb H37Rv DESX1. Mice (n3 per time point plus 1 naive
uninfected control) were sacriﬁced at days 1, 3, 7, 14 and 28 post-
infection. At each time point serum samples were taken and the
lungs were resuspended in 2 mls of DMEM medium (Sigma
Aldrich) plus 1.4 mg/ml collagenase (Sigma Aldrich) and 60 mg/ml
DNase I (Sigma Aldrich). Following 45 min incubation at 37 C the
lungs were homogenised and the samples were centrifuged. The
supernatant was saved as lung lysate and the lymphocytes were
isolated from the cell pellet using Lympholyte M (CedarLane) and
then processed for ﬂow cytometry. At day 1 and day 28 post-
infection one lung per mouse was homogenised and plated out
for CFU as noted above in Mtb growth.
2.6. Modiﬁed trans-well assay
MDMs,matured for 6 days at 5105 cells perwell, were infected
with Mtb as above and 5  105 PBMCs added in 12-well millicell
hanging culture inserts with 5m ﬁlters, which would allow both
monocytes and lymphocytes to pass through (Merck Millipore).
Following 24 h infection (wmaximal fractalkine production) the
inserts were removed and the cells were harvested by centrifuging
the supernatant and by scraping for adherent cells prior to counting
in a haemocytometer and ﬂow cytometry staining.
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The 12-plex human cytokine array MPXHCYTO-60K-12 (Merck
Millipore), human fractalkine single-plexMPXHCYTO-60K-01 (Merck
Millipore), murine single-plex MPXMCYP2-73K-01(Merck Millipore)
and matrix metalloproteinase panel 1 HMMP1-55K-03 (Merck Milli-
pore) were carried out as per the manufacturer’s instructions.
2.8. Necrosis assay
LDH release was quantiﬁed at speciﬁed time points by using the
cytotoxicity detection kit (Roche Diagnostics), according to the
manufacturer’s instructions. The maximum and background con-
trols used were 0.1% Triton X-100-treated cells (maximum) and
uninfected cells (background). Values were calculated by using the
following equation: % LDH release: (sample-background)/
(maximum-background)  100. The necrosis positive control was
0.1% Triton X-100 (Sigma).
2.9. Bronchoalveolar lavage (BAL) samples
BAL samples were obtained from the Tuberculosis Service at St
Marys hospital, transferred to CL3 facilities and following passage
through a 70m cell strainer (VWR) and centrifugation the cells were
pelleted and frozen in foetal calf serum plus 10% DMSO (Sigma
Aldrich) at 80 C until use in ﬂow cytometry. The supernatant or
BAL ﬁltrate was ﬁltered through a 0.2m ﬁlter and stored at 20 C
until use. BAL samples were also acquired from healthy and asth-
matic individuals too.
3. Results
3.1. Mtb infection of THP-1 macrophages results in the production
of fractalkine which is mediated by the virulence-associated ESX1
We previously constructed a Mtb H37Rv mutant in the RD1
region Rv3871-Rv3879which has a defective ESX1 secretion systemFigure 1. Mtb H37Rv induces the production of key macrophage cytokines in a non-ES
necrosis factor alpha (TNF-a), b) interleukin 6 (IL-6), c) granulocyte colony stimulating factor
inﬂammatory protein 1beta (MIP-1B) and f) regulated on activation normal T cell expressed a
H37Rv infected (Rv), H37Rv DESX1 infected (DESX1), H37Rv DESX1 complemented (C) an
representative of triplicate experiments and the bars shown are standard deviations.[5]. We infected the adherent THP-1 cells at a multiplicity of
infection (M.O.I) of 10:1 with the wild-type and mutant strains and
took supernatants at 24 h and 48 h post-infection (since the H37Rv
ESX1 mutant exhibits a defect in cellular necrosis at 72 h post
infection [5]). Along with the mutant and wild-type, infection was
also carried out with a complemented mutant [5] and controls
included uninfected and LPS-treated adherent human cells.
Secretion of all of the innate cytokines measured in response to
infection with Mtb was similar to that with infection with the Mtb
DESX1 mutant (Figure 1aef), with the exception of the chemokine
fractalkine (Figure 2a, P ¼ 0.041). Therefore, uniquely among the
panel of chemokines and cytokines evaluated, fractalkine induction
at 24 h post-infection in Mtb-infected THP-1 cells is ESX1-
mediated. This difference was also observed at 48 h post-infec-
tion (data not shown) but in both cases was only observed in
resting macrophages, the suggested preferred interstitial niche of
the tubercle bacillus [14] and was not seen in cells activated by the
Th1 cytokine interferon-g (IFN-g; Figure 2b).
3.2. Fractalkine production is ESX1-mediated in primary human
MDMs and does not induce cellular necrosis
We also determined that fractalkine production was ESX1-
dependent in primary human MDMs (Figure 2c, P ¼ 0.040). In
contrast, there was no production of fractalkine noted in mruine
macrophages. The ESX1 region of Mtb is also associated with
increased cellular necrosis and cellular egress at 72 h post-infection
[5] so we assessed whether fractalkine plays a role in cellular ne-
crosis at this time point using an anti-fractalkine monoclonal
antibody, recombinant fractalkine and Triton-X 100 induction of
necrosis as a positive control. Infection with Mtb H37Rv resulted in
the induction of necrosis similar to the Triton-X 100-treated posi-
tive control but this was not reduced by the addition of anti-
fractalkine (Figure 2d). Moreover, the addition of fractalkine itself
did not increase necrosis over the basal uninfected level conﬁrming
that fractalkine does not induce macrophage necrosis in this
system.X1 dependent manner (24 h post-infection) Multiplex cytokine array for a) tumour
(G-CSF), d) granulocyte macrophage colony stimulating factor (GM-CSF), e) macrophage
nd secreted (RANTES). Samples analysed were PMA-treated THP-1 cells uninfected (U),
d LPS (10 ng/ml) stimulated for 24 h hours at an M.O.I. of 10:1. Pg ¼ pg/ml. This is
Figure 2. The production of fractalkine from THP-1 cells and human macrophages at 24 h post-infection is ESX1-dependent and does not cause necrosis. a) Fractalkine
production as measured by a multiplex cytokine assay from THP-1 cells activated overnight with PMA and infected with an M.O.I. of 10:1 with H37Rv (Rv), H37Rv DESX1 (DESX1),
complemented H37Rv DESX1 (C), untreated (U) or LPS treated (LPS, 10 ng/ml). b) Fractalkine production from THP-1 cells plus overnight IFN-g (I) stimulation and infected as a. c)
Fractalkine production from monocyte-derived macrophages from healthy controls and infected as a. d) Host cell necrosis, as measured by lactate dehydrogenase release, from
human monocyte-derived macrophages at 72 h post-infection at an M.O.I. of 10:1. U ¼ uninfected, FKN ¼ treated with FKN, LPS ¼ LPS treatment at 10 ng/ml, RV ¼ H37Rv, RV/
AF ¼ Rv plus anti-fractalkine, þ ¼ Triton X-100 treated. Each experiment has been repeated three times, from three different healthy donors if primary cells. Statistical analyses
were carried out using the ManneWhitney non-parametric test.
S.M. Hingley-Wilson et al. / Tuberculosis 94 (2014) 262e270 2653.3. Matrix metalloproteinase 1, 2, 7, 9 and 10 production from
Mtb-infected human macrophages and epithelial cells is not ESX1-
mediated
Elucidation of the fundamental role of M. marinum-induced
ESX-1-dependent MMP-9 secretion in zebraﬁsh embryos [4] after
we generated the above data prompted us to investigate ESX1-
dependence of MMP-9 secretion in our human system. We
assessed production of MMP-9 in THP-1 cells, both with and
without IFN-g, and in human MDMs and found no difference be-
tween Mtb H37Rv and the Mtb DESX1 mutant. This was also the
case with cells activated with conditioned media from infected
macrophages (Figure 3aec). Although we observed substantial
production of MMP9 in human alveolar epithelial cells (A549 cell
line; Figure 3d) there was no ESX-1 mediated difference. The
zebraﬁsh immune system differs substantially from the human, so
we studied several other MMPs (1, 2, 7 and 10) to see if an alter-
nativeMMPmight be acting in the place of the zebraﬁshMMP9 and
there was no observable ESX1-mediated difference in the MMPs 1,
2 7 or 10 (Supplementary Figure 1).
3.4. Mtb ESX1-mediated fractalkine production results in Syk-
dependent monocytic cell recruitment and M. tuberculosis niche
expansion in humans
Fractalkine’s primary function is as a chemoattractant to both
monocytic and lymphocytic cells. Accordingly we set up a modi-
ﬁed transwell assay (see Figure 4a) in order to test for Mtb-
induced ESX1-dependent cellular migration. Direct observationalcounting in a haemocytometer on blinded samples revealed a
reduction in cellular migration in the Mtb DESX1-infected trans-
well experiment in all three healthy donors. This difference was
signiﬁcantly different to wild-type-infected cells and was restored
by complementation of the ESX1 mutation (Figure 4b). The cyto-
plasmic tyrosine kinase Syk is required for monocyte/macrophage
chemotaxis to fractalkine [15] and addition of the Syk inhibitor
picetannol resulted in a similar migratory reduction to that
observed with Mtb DESX1 conﬁrming that Syk-dependent ESX1-
mediated fractalkine production results in cellular migration to-
wards Mtb-infected cells.
We then determined the nature of these migratory cells using
ﬂow cytometry. We stained for dead cells using a live/dead
discrimination kit then stained with the ﬂuorochrome-conjugated
antibodies, CD3-Pe-Cy7 and CD11b-APC-Cy7. CD3 is a pan-T cell
marker and CD11b is an integrin also known as Mac-1 often used as
a pan monocyte-macrophage marker and used in murine studies
for macrophage depletion [16]. While the CD3þ cell number
exhibited no difference (Figure 4c), the number of CD11bþ cells was
signiﬁcantly reduced in the Mtb DESX1-infected transwell assay
when compared to the Mtb wild-type-infected cells (Figure 4d). A
similar reduction was seen in CD11bþ cell migration when the
wild-type infected cells were treated with an anti-fractalkine
antibody or the Syk inhibitor picetannol, but not with an anti-TNF
antibody (data not shown). Thus, Mtb ESX1-mediated fractalkine
production results in enhanced recruitment of CD11bþ monocytic
cells, the niche for the tubercle bacillus, but not in CD3þ T cells,
many subtypes of which are implicated in protection against
tuberculosis.
Figure 3. MMP-9 is produced by human macrophages at 24 h post-infection, but is not ESX1-mediated. Cells were infected at an M.O.I. of 10:1 or exposed to conditioned
medium for 24 h. U ¼ uninfected, Rv ¼Mtb H37Rv, DESX1 ¼Mtb ESX1 mutant, C ¼ complemented ESX1 mutant, P ¼Mtb plus piceatannol, Ab ¼Mtb plus anti-fractalkine antibody,
coRv ¼ conditioned medium from Rv infected cells, coD ¼ conditioned medium from ESX-1 infected cells, LPS ¼ 1 ng/ml a) THP-1 cells, b) THP-1 cells plus overnight 10 U IFN-g, c)
MDMs, d) A549 alveolar epithelial cells. Data is representative of two replicates and 2 independent experiments and shows standard error bars.
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percentage infection and cellular spread
The Mtb ESX1 mutant does not exhibit a growth defect in hu-
man cells or in vivo in the murine model [5] and this was also
determined to be the case in the transwell system by plating outFigure 4. ESX1-mediated fractalkine production results in migration of CD11bD cells
infected MDMs and PBMCs, b) migrating cells as measured per ml on a haemocytometer afte
ﬂow cytometric determination of CD11bþmigratory cells. Each graph is representative of th
out using a Mann Whitney statistical analysis for ﬁgures bed.colony forming units (CFU) from 0, 24, 48 and 72 h post-infection
plus and minus anti-fractalkine antibody (data not shown). How-
ever, we hypothesised that the increased recruitment of niche cells
for the bacilli would result in an increase in the percentage infec-
tion rate of the cells early after infection. Therefore, ﬂuorescently
labelled wild-type bacteria (FITC-labelledMtb H37Rv) were used to. a) Modiﬁed trans-well assay set up shown per well with transwell insert and with
r trypan blue staining, c) ﬂow cytometric determination of CD3þmigrating cells and d)
ree independent experiments with standard error bars. Statistical analyses were carried
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without anti-fractalkine antibody and the numbers of infected cells
determined using ﬂow cytometry in the FITC channel. The per-
centage infected cells were signiﬁcantly reduced upon treatment
with anti-fractalkine, which reduces CD11bþ monocytic cellular
migration (Figure 5a, P < 0.05).
Direct observation, again blinded, of the infected monolayers
was also carried out following Ziehl-Neelsen staining. This
conﬁrmed the above ﬁnding, showing reduced infection levels in
the anti-fractalkine treated wells 72 h post-infection (Figure 5b).
This also enabled us to count the number of bacilli per infected cell
(Figure 5c) and there were signiﬁcantly higher (P¼ 0.026) numbers
of intracellular bacteria associated with the anti-fractalkine treated
cells (mean ¼ 35) than with the control (mean ¼ 12) at this time
point. Representative ﬁelds are shown in Figure 5deg, where 5f and
g show the anti-fractalkine treated wells and 5d and e the un-
treated wells. Blocking fractalkine thus results in higher numbers of
bacilli per cell and fewer infected cells, indicating that fractalkine-
mediated monocyte inﬂux early in infection aids in bacillary
spread. ESX1-mediated fractalkine production from infected mac-
rophages thus results in increased inﬂux and infection of monocytic
cells and promotes bacillary dissemination.
3.6. Increased fractalkine levels are associated with granulomatous
disease and increased CD11bþ monocytic cellular inﬁltration at
disease sites in humans
We sought to determine the involvement of fractalkine in
granulomatous disease, employing sarcoidosis as an example of a
non-TB disease associated with the formation of granulomas in the
lung. Therefore, we obtained bronchoalveolar lavage (BAL) ﬂuid
from patients with TB (n13), sarcoidosis (n3), asthma (n3) and
normal healthy (n3) controls, ﬁltered the supernatants and
measured fractalkine levels using a multiplex cytokine assay. The
BAL ﬂuid from TB patients contained signiﬁcantly higher levels of
fractalkine than the inﬂammatory but non-granulomatous lungFigure 5. The addition of anti-fractalkine results in reduced rates of cellular infection an
infected cells after addition of the anti-fractalkine antibody and as measured by ﬂow cyto
malachite green counter-stained. Cells were counted using oil immersion light microscopy
intracellular bacteria from infected monolayers as 5b. Representative ﬁelds are shown in F
untreated wells. Figures each represent three independent experiments from different dono
and b and a student’s t-test for 5c.(For interpretation of the references to colour in this ﬁgdisease asthma (P ¼ 0.001) and the healthy controls (P ¼ 0.004,
Figure 6a). Sarcoidosis also exhibited signiﬁcantly increased levels
of fractalkine compared to asthma (P ¼ 0.026) and healthy controls
(0.028) suggesting an association with granulomatous disease.
In 5 patients with active cavitatory pulmonary tuberculosis with
consolidation, we enumerated the number of CD11bþ and CD3þ
cells by ﬂow-cytometry in BAL and correlated thesewith fractalkine
levels (Figure 6b) in ﬁltrates of the same BAL samples. The levels of
fractalkine at the site of disease clearly correlated with the number
of CD11bþ cells (Figure 6c, P¼ 0.021), but not CD3þ cells (Figure 6d,
P ¼ 0.383), thus suggesting that increased fractalkine in the lung is
signiﬁcantly associated with increasedmonocytic cell numbers and
niche expansion. This increase in available niche cells would be
expected to result in increased cellular infection and egress,
potentially associated with more disseminated disease in the lung.
3.7. Mtb-mediated fractalkine production and CD11bþ cellular
migration was not observed in the murine model of infection
A major limitation of the murine model of infection with Mtb is
the lack of granuloma formation. We intra-nasally infected Balb/C
mice with the Mtb DESX1 mutant and wild-type strains. No ESX1-
mediated differential fractalkine (generally called lymphotactin in
the mouse with structural differences to the human homologue
[17]) productionwas observed in the lung lysates (as had been seen
previously in murine macrophages in vitro) and no differential
inﬁltration of CD11bþ or CD3þ cells was observed between the
mutant andwild-type at days 1, 3, 7,14, 21 and 28 (data not shown).
In addition, there was no difference noted in colony forming units
as previously determined [5].
4. Discussion
The early events in TB infection are likely critical to determining
whether the outcome favours the host or the pathogen. Following
inhalation the bacilli must infect and then replicate within itsd increased bacillary numbers per cell. a) % reduction in infection of Mtb H37Rv-FITC
metry, b) % cells infected from infected monolayers stained with carbol fuschein and
at a magniﬁcation of  100 and from at least 10 different ﬁelds, c) enumeration of
igure 5deg, where 5f and g show the anti-fractalkine treated wells and 5d and e the
rs. Statistical analyses were carried out using a Dunns multiple comparison test for 5a
ure legend, the reader is referred to the web version of this article.)
Figure 6. Increased FKN levels are associated with granulomatous disease in humans and correlate with increased CD11bD and not CD3D cellular inﬁltration in the human
lung. a) FKN levels as measured by multiplex cytokine assay in BAL samples from TB patients (n13), asthmatic (n3), healthy controls (n3) and sarcoid patients (n3), b) FKN levels in
BAL ﬁltrate from patients with active tuberculosis (duplicate samples), c) log number of CD11bþ cells present in BAL samples from patients with active tuberculosis versus log FKN
levels and d) log number CD3bþ cells present in BAL samples from patients with active tuberculosis versus log FKN levels. Statistical analyses were carried out using a Manne
Whitney statistical analysis for 6a and Pearsons rank test for 6c and d.
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of further permissive niche cells will halt the spread of infection
and conversely the inﬂux of niche cells would enable the infection
to spread. Here we show that the tubercle bacillus utilises the very
cell-type evolved to destroy invading pathogens in order to
establish and locally disseminate infection by signalling sibling-
cells and increasing its permissive niche. Our ﬁndings suggest
that the Mtb-mediated inﬂux of uninfected niche cells allows the
bacteria to infect new host cells, disseminate and to set up a foot-
hold of infection within the human lung.
Elegant studies in the M. marinum-infected zebraﬁsh model of
infection describe how this early aggregation of macrophages,
termed a granuloma, is utilised by the bacilli to facilitate bacterial
growth and the spread of infection [3]. However, although the
M. marinum-zebraﬁsh model has fundamentally advanced our
understanding of early Mtb infection, zebraﬁsh do not have lungs
and so whether or not ESX1-dependent cellular aggregation and
infectious dissemination occurs in the lung is unknown. In addition,
zebraﬁsh embryos lack a fractalkine homologue and also lack T and
B cells [18], so whether preferential recruitment of macrophages
also occurs in models with both lymphoid and myeloid cells in
humans needs to be determined. Using a non-growth deﬁcient Mtb
ESX1 mutant, unlike the M. marinum mutant, here we provide the
ﬁrst evidence of ESX1-dependent speciﬁc fractalkine-mediated
chemotaxis of monocytic cells to infected macrophages in the
presence of lymphocytes. We further demonstrate a relationship
betweenmonocyte inﬁltration and fractalkine levels in tuberculous
human lung.
The chemokine fractalkine (CX3CL1) exists in a class of its own
containing a unique C-X3-C motif and can exist in both membrane-
bound and soluble forms, the latter of which has potent monocyte
and T cell chemoattractant properties, higher than the chemokine
RANTES [19]. Fractalkine is secreted by many cell types including
macrophages and can exist as a membrane bound molecule only inendothelial cells due to the presence of a mucin-like stalk, which is
cleaved from the soluble form [20]. Although fractalkine has been
determined to be present at the site of disease in patients with
pulmonary tuberculosis [21,22] its role in human tuberculosis was
hitherto unknown. The cognate receptor for fractalkine, CX3CR1, is
necessary for migration and not adhesion and shown to be
expressed by themajority of monocytes, NK cells and about 10e15%
of T cells [23]. Interestingly, CX3CR1 is a requisite for rapid tissue
invasion of resident monocytes at the site of infection in mice
peritoneally infected with Listeria monocytogenes [24].
We identiﬁed ESX-1-dependent induction of the chemokine
fractalkine from host macrophages. A modiﬁed trans-well migra-
tion assay revealed ESX-1-mediated FKN-dependent migration of
CD11bþ (a pan-macrophagemarker) cells, with no signiﬁcant effect
upon migration of CD3þ (pan-T cell marker) cells at this sample
size. The recruitment of uninfected macrophages by fractalkine by
the Mtb-infected macrophage resulted in productive infection,
increasing the proportion of infected cells and thus bacillary
dispersal and dissemination. The addition of anti-fractalkine
resulted in fewer infected cells with higher bacterial loads.
We next assessed the role of fractalkine in vivo. In our murine
experiments there was no fractalkine production and no ESX1-
mediated difference in cellular recruitment of CD11bþ or CD3þ
cells into the murine lung, suggesting this artiﬁcial model system
which lacks granuloma formation and which, unlike the zebraﬁsh-
M. marinum model, is not a natural host/pathogen pair, is sub-
stantially different to human infection. In vivo in the human lung,
fractalkine levels were elevated in BAL from TB patients compared
to healthy controls and asthmatic controls and were moreover
strongly correlated with the extent of monocytic cell inﬁltration.
Fractalkine levels were also elevated in BAL from sarcoidosis pa-
tients, suggesting an association of fractalkine with pathogenesis of
granulomatous disease, consistent with earlier observations in TB,
sarcoidosis and Wegeners granulomatosis [22,25].
S.M. Hingley-Wilson et al. / Tuberculosis 94 (2014) 262e270 269The role of fractalkine in granulomatous disease clearly requires
further investigation and, in the case of TB, it would be of interest to
investigate ESX-1-mediated fractalkine-induction in a human
in vitro mycobacterial granuloma model similar to that of Birkness
et al. where the involvement of the cytokines IFN-g and TNF-a was
elegantly dissected [26]. Fractalkine itself acts as a potent polariser
of the Th1 immune response and its role in the adaptive immune
response toMtb remains to be fully elucidated. Increased fractalkine
has also been associated with factors which increase the risk of the
development of TB disease and of disease reactivation including age
[27] and HIV infection [28]. Further work is now required to
correlate fractalkine levels with bacillary burden and patient out-
comes including risk of disease progression and response to therapy.
The type VII secretion system ESX1 system has also been
implicated in cellular necrosis leading to increased cellular egress
later in infection [5] and fractalkine could represent an early stage
recruiting permissive cells prior to their release by necrosis. Indeed,
abrogating the effect of fractalkine resulted in reduced CD11bþ
cellular recruitment and reduced percentage infection, without
affecting cellular necrosis. The ESX1-secreted protein ESAT-6 was
responsible for the MMP9 production from neighbouring epithelial
cells inM.marinum-infected zebraﬁsh embryos [5,29]. The complex
secretory co-dependence of this system makes the exact role of
each of the ESX1-secreted proteins difﬁcult to dissect and this work
is currently ongoing.
In conclusion, Mtb ESX1-fractalkine-mediated CD11bþ cellular
migration may play a role in establishment of a foothold in initial
infection,maintenanceandspreadofbacilli throughnicheexpansion.
Our data moreover suggest that the fractalkine/fractalkine receptor
axis could represent an attractive target for novel immunomodula-
tory interventions for treatment or prevention of tuberculosis infec-
tion. A human fractalkine analogue which inhibits CD11bþ
chemotaxis in human MDM’s has recently been described [30] and
ourﬁndings support the clinical evaluationof this as a potential novel
strategy to reduce the spread of the tubercle bacilli in vivo.
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